Ann Fam Med. 2022 Apr 1;20(20 Suppl 1):2639. doi: 10.1370/afm.20.s1.2639.
COVID-19 has caused disruptions in health care, in particular cancer screenings. The primary aim of our work was to evaluate the degree to which populations were accepting of home-based screenings for colorectal cancer (CRC) and cervical cancer (primary HPV testing). Three groups of adults having distinct health burdens which may affect acceptance of home-based cancer screening were identified through outpatient electronic medical records as follows as either having survived a COVID hospitalization, having been positive for non-COVID respiratory illness or having type 2 diabetes. 132 respondents (58% female) completed an online survey with hypothetical cases about their acceptance of home-based CRC or cervical cancer screening. Among females, urine and vaginal screening for primary HPV testing was acceptable to 64% and 59%, respectively. Among both males and females, CRC home screening with fecal immunochemical test (FIT) or Cologuard was acceptable to 60% of the respondents. When adjusting for education, women with a positive attitude toward home-based urine /vaginal screening were 49 times and 23 times more likely to have a positive attitude toward CRC screening (aOR=48.7 (95% CI: 7.1, 337) and aOR=23.2 (95% CI: 3.8, 142), respectively). This report indicates that home-based cancer screens for CRC and primary HPV testing are acceptable to men and women and may allow for greater compliance with screening in the future.
COVID-19 对医疗保健造成了干扰,尤其是癌症筛查。我们工作的主要目的是评估人群对基于家庭的结直肠癌(CRC)和宫颈癌(HPV 初筛)筛查的接受程度。通过门诊电子病历,确定了三组具有不同健康负担的成年人,他们可能会影响对基于家庭的癌症筛查的接受程度,这些负担包括 COVID 住院、非 COVID 呼吸道疾病阳性或 2 型糖尿病。132 名受访者(58%为女性)完成了一项在线调查,调查了他们对基于家庭的 CRC 或宫颈癌筛查的接受程度。在女性中,尿液和阴道 HPV 初筛分别有 64%和 59%的人接受。在男性和女性中,粪便免疫化学检测(FIT)或 Cologuard 进行 CRC 家庭筛查的接受程度均为 60%。在调整教育因素后,对家庭尿液/阴道筛查持积极态度的女性对 CRC 筛查持积极态度的可能性分别为 49 倍和 23 倍(优势比[aOR]=48.7(95%CI:7.1,337)和 aOR=23.2(95%CI:3.8,142))。本报告表明,基于家庭的 CRC 和 HPV 初筛是男性和女性都可以接受的,并且可能会在未来提高筛查的依从性。